Covid19 Clinical Trials 2022

Browse 240 Covid 19 Medical Studies Across 500 Cities

42 Phase 3 Trial · 1714 Covid 19 Clinics

Reviewed by Michael Gill, B. Sc.
Phase-Based Progress Estimates
1
Effectiveness
1
Safety

Self-proningfor COVID19 (disease)

Toronto, Canada
18+
All Sexes
The rapid development of safe and effective COVID-19 treatment is a global health priority. Numerous studies evaluating therapies for this disease are currently underway, but the majority of these are in hospitalized patients with severe illness. Consequently, there is an urgent need to identify therapies that prevent mild COVID-19 cases in the community from becoming more severe. "Proning" or lying face down in bed has been shown to improve breathing and oxygen levels in COVID-19 patients, reducing the need for breathing tubes and ventilators and increasing survival. The current study will investigate whether proning and repositioning (lying on one's side or sitting up) can prevent mild cases of COVID-19 from becoming more severe resulting in fewer hospitalizations and death. A randomized controlled trial will be used to reduce the risk of bias when testing this intervention. Unvaccinated or partially vaccinated adult patients with a positive COVID-19 test willing to participate and well enough to be treated outside the hospital will be randomly assigned to one of two groups: a home-proning intervention group with instructions and daily reminders to prone and reposition during the day and at night, and a standard care group. Our goal is to assess whether home-proning/repositioning leads to fewer hospitalizations and death when compared with standard care. We'll also compare recovery time, use of antibiotics and follow up emergency department visits between these two groups. The current pilot study will assess the feasibility of a larger investigation or "main trial", meaning it will be small scale test of methods and procedures to be used on a larger scale.
Recruiting
Has No Placebo
Phase-Based Progress Estimates
1
Effectiveness
1
Safety

Full Interventionfor COVID-19

Atlanta, GA
18+
All Sexes
The ENSPIRE study is a cluster-randomized comparative effectiveness trial being conducted within long-term care and residential facilities that will test a communication and engagement strategy for increasing COVID-19 booster vaccination rates against an enhanced usual care comparator (Centers for Disease Control and Prevention vaccine education and communication materials) among facility staff. The communication and engagement strategy being tested includes (1) the development of materials co-designed with and tailored to facility staff whose primary language is a language other than English or who are from certain cultural affinity groups and (2) the distribution of the developed materials by members of the language/cultural affinity groups with peer advocacy activities (full intervention). The study is being conducted in Washington state and Georgia. Long-term care/residential facilities will be asked to furnish their staff booster rate at 4 timepoints: pre-intervention, and one month (timepoint 1), 3 months (timepoint 2), and 6 months (timepoint 3) post-intervention. Staff at participating long-term care facilities will be invited to complete three online surveys at 3 timepoints: pre-intervention, 3 months post-intervention and 6 months post-intervention. Long-term care facilities will be randomized to a trial arm following the pre-intervention data collection.
Recruiting
Has No Placebo
25 Covid 19 Clinical Trials Near Me
Knoxville, TN
Toronto, Canada
Pointe-Claire, Canada
Quebec, Canada
More Trial Locations
An interactive map to display trial locations for EDP Biotech, LMC Manna - Bayview CPU, Manna Research Inc, CHU de Québec Université Laval, and 111 more locations.
Most Popular References for Covid 19 Clinical Trials
Frequency
Citation
Top Hospitals for Covid 19 Clinical Trials
Location
Active Covid 19 Clinical Trials
All Time Trials for Covid 19
First Recorded Covid 19 Trial
Trials
Sunnybrook Health Sciences Centre, Toronto, Ontario
5
13
2016
Stanford University, Stanford, California
5
21
2017
Emory Vaccine Center - The Hope Clinic, Decatur, Georgia
4
12
2020
Mayo Clinic in Rochester, Rochester, Minnesota
4
12
2020
Top Treatments for Covid 19 Clinical Trials
Top Cities for Covid 19 Clinical Trials
City
Active Covid 19 Clinical Trials
Top Active Site for Covid 19 Clinical Trials
Trial List
Miami, Florida
59
Westchester General Hospital
Houston, Texas
41
Baylor College of Medicine - Molecular Virology and Microbiology
New York, New York
37
New York University School of Medicine - Langone Medical Center - Vaccine Center
Toronto, Ontario
30
Sunnybrook Health Sciences Centre
Phase 3 Covid 19 Clinical Trials
Clinical Trial
Began Recruiting Date
Phase
3/7/2022
Phase 2 & 3
2/20/2022
Phase 2 & 3
12/21/2021
Phase 3
Recently Completed Studies with FDA Approved Treatments for Covid 19
Treatment
Year
Mechanism of Action
Sponsor
Active Covid 19 Clinical Trials
COVID-HIG
2021
Emergent BioSolutions
0
Q-Griffithsin
2021
Kenneth Palmer
0
REGN14256
2021
Regeneron Pharmaceuticals
0
C21
2021
Vicore Pharma AB
0
Ritonavir
2021
Ritonavir
Pfizer
0
Estradiol Cypionate 5 MG/ML
2021
Estradiol cypionate
Tulane University
0
Danicopan
2021
Danicopan
National Institute of Allergy and Infectious Diseases (NIAID)
0
Quadrivalent Inactivated Influenza High Dose
2021
Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) + Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) + Influenza A virus A/California/7/2009 X-179A (H1N1) antigen (formaldehyde inactivated)
Sanofi Pasteur, a Sanofi Company
0
PF-07321332
2021
Nirmatrelvir
Pfizer
0
sotrovimab
2021
Sotrovimab
Vir Biotechnology, Inc.
1

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 8th, 2021

Last Reviewed: August 20th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.